Insider Selling: GeneDx Holdings Corp. (NASDAQ:WGS) CFO Sells 35,506 Shares of Stock

GeneDx Holdings Corp. (NASDAQ:WGS) CFO Kevin Feeley sold 35,506 shares of GeneDx stock in a transaction on Tuesday, January 7th. The stock was sold at an average price of $93.82, for a total transaction of $3,331,172.92. Following the sale, the chief financial officer now owns 2,472 shares of the company’s stock, valued at $231,923.04. The trade was a 93.49 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Kevin Feeley also recently made the following trade(s):

• On Thursday, January 2nd, Kevin Feeley sold 1,430 shares of GeneDx stock. The stock was sold at an average price of $76.04, for a total value of $108,737.20.
• On Monday, December 16th, Kevin Feeley sold 3,728 shares of GeneDx stock. The shares were sold at an average price of $76.75, for a total value of $286,124.00.
• On Monday, December 9th, Kevin Feeley sold 1,137 shares of GeneDx stock. The stock was sold at an average price of $76.37, for a total value of $86,832.69.
• On Monday, December 2nd, Kevin Feeley sold 263 shares of GeneDx stock. The stock was sold at an average price of $78.39, for a total transaction of $20,616.57.
• On Thursday, November 21st, Kevin Feeley sold 12,019 shares of GeneDx stock. The shares were sold at an average price of $73.76, for a total transaction of $886,521.44.
• On Tuesday, October 29th, Kevin Feeley sold 274 shares of GeneDx stock. The stock was sold at an average price of $66.60, for a total value of $18,248.40.

GeneDx Trading Down 7.4 %

WGS stock opened at $89.38 on Friday. GeneDx Holdings Corp. has a 12-month low of $2.85 and a 12-month high of $98.87. The business’s 50-day moving average is $78.01 and its 200 day moving average is $53.19. The company has a current ratio of 2.40, a quick ratio of 2.27 and a debt-to-equity ratio of 0.25. The stock has a market cap of $2.46 billion, a price-to-earnings ratio of -28.74 and a beta of 2.02.

GeneDx (NASDAQ:WGS) last issued its quarterly earnings results on Tuesday, October 29th. The company reported $0.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.25. GeneDx had a negative return on equity of 13.35% and a negative net margin of 31.25%. The firm had revenue of $76.90 million for the quarter, compared to analyst estimates of $64.98 million. During the same period in the previous year, the company posted ($0.82) earnings per share. The business’s revenue was up 44.3% on a year-over-year basis. On average, sell-side analysts anticipate that GeneDx Holdings Corp. will post -0.24 EPS for the current fiscal year.

Institutional Investors Weigh In On GeneDx

A number of large investors have recently modified their holdings of WGS. Acadian Asset Management LLC purchased a new position in shares of GeneDx in the second quarter worth about $34,000. CWM LLC acquired a new stake in GeneDx in the 3rd quarter valued at about $89,000. SG Americas Securities LLC purchased a new position in GeneDx in the 3rd quarter worth approximately $198,000. Point72 DIFC Ltd acquired a new position in shares of GeneDx during the 3rd quarter worth approximately $220,000. Finally, Palumbo Wealth Management LLC purchased a new stake in shares of GeneDx in the third quarter valued at approximately $287,000. Hedge funds and other institutional investors own 61.72% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently commented on the stock. TD Cowen raised their price target on shares of GeneDx from $75.00 to $118.00 and gave the company a “buy” rating in a research report on Tuesday. The Goldman Sachs Group raised their target price on GeneDx from $54.00 to $70.00 and gave the company a “neutral” rating in a research report on Wednesday, October 30th. Wells Fargo & Company increased their price target on GeneDx from $34.00 to $75.00 and gave the stock an “equal weight” rating in a research report on Wednesday, October 30th. Finally, Craig Hallum boosted their price objective on GeneDx from $70.00 to $95.00 and gave the company a “buy” rating in a research report on Wednesday, October 30th. Three research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to MarketBeat, GeneDx has an average rating of “Moderate Buy” and a consensus target price of $70.67.

GeneDx Company Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.